EUVIMEDEUVIMED entdecken
Open Access

Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa

Gabriel Cabot iD, Kihun Kim iD, Brian L Mark iD, Antonio Oliver iD, Mazdak Khajehpour iD

Antimicrobial Agents and Chemotherapy · 16.02.2023 · 67 (2)

DOI: 10.1128/aac.01409-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 16.02.2023. Verfasst von Gabriel Cabot und 4 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several Pseudomonas aeruginosa AmpC mutants have emerged that exhibit enhanced activity against ceftazidime and ceftolozane, while also evading inhibition by avibactam. Interestingly, P. aeruginosa strains harboring these AmpC mutations fortuitously exhibit enhanced carbapenem susceptibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPseudomonas InfectionsHumansAnti-Bacterial AgentsImipenemDrug CombinationsCephalosporinsTazobactamCeftazidimeMutationMicrobial Sensitivity TestsAzabicyclo Compounds

Stichwörter der Autor:innen

AmpCPseudomonas aeruginosaantibiotic resistancebeta-lactamaseimipenem

Substanzen

ceftolozaneAnti-Bacterial AgentsImipenemDrug Combinationsceftolozane, tazobactam drug combinationCephalosporinsTazobactamCeftazidimeAzabicyclo Compounds

Autor:innen und Institutionen

  • Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Department of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.

ORCID-Profile: Gabriel Cabot, Kihun Kim, Brian L Mark, Antonio Oliver, Mazdak Khajehpour

Förderung

  • Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Cabot, G., Kim, K., Mark, B. L., Oliver, A., & Khajehpour, M. (2023). Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 67(2). https://doi.org/10.1128/aac.01409-22

Vancouver

Cabot G, Kim K, Mark BL, Oliver A, Khajehpour M. Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2023;67(2). doi:10.1128/aac.01409-22

BibTeX
@article{Cabot2023,
  author = {Cabot, Gabriel and Kim, Kihun and Mark, Brian L and Oliver, Antonio and Khajehpour, Mazdak},
  title = {Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {2},
  doi = {10.1128/aac.01409-22}
}
Kostenlos starten →